<PAGE>
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 24, 1997
ROBERTS PHARMACEUTICAL CORPORATION
- --------------------------------------------------------------------------------
(exact name of registrant as specified in its charter
New Jersey 1-1-432 22-2429994
- --------------- ----------- --------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: 908-389-1182
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Former name or former address, if changed from last report)
<PAGE>
-2-
Item 5. Other Events
------------
Roberts Pharmaceutical Corporation announced today that its new
drug Agrylin/TM/ (anagrelide hydrochloride) has successfully completed both
clinical and labeling reviews by the Health Protection Branch (HPB) and the
product is cleared for marketing in Canada. The Company's wholly owned
subsidiary Roberts Pharmaceutical Canada will market Agrylin/TM/ in Canada.
Roberts expects to launch the product in Canada in early January 1998.
Agrylin/TM/, having been launched in the U.S. in March of this
year is the first drug cleared for marketing by both the FDA and HPB for the
treatment of essential thrombocythemia, a life threatening condition
characterized by elevated blood platelet counts. Agrylin/TM/ is currently under
review for approval in the European Union. The Company commented that
Agrylin/TM/ is the first drug to emerge from their product pipeline with the
potential for worldwide marketing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
ROBERTS PHARMACEUTICAL CORPORATION
----------------------------------
(Registrant)
Date: November 25, 1997 By: /s/ Anthony A. Rascio
------------------------------
Anthony A. Rascio
Vice President
